<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48784">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02137928</url>
  </required_header>
  <id_info>
    <org_study_id>yanghs2014</org_study_id>
    <nct_id>NCT02137928</nct_id>
  </id_info>
  <brief_title>Carboplatin Periocular Injection for Retinoblastoma</brief_title>
  <official_title>Carboplatin Periocular Injection in the Treatment for Retinoblastoma--A Single Center, Randomized Study to Evaluate the Efficacy of Ranibizumab in Subjects With Retinoblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the clinical efficacy of  periocular injections of carboplatin
      together with chemotherapy in the treatment of Retinoblastoma as compared to chemotherapy
      alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a phase II open label interventional case series. Patients with
      retinoblastoma will be randomized to receive chemotherapy with or without  periocular
      injections of carboplatin at a dose of 20mg/2 ml. Patients will receive carboplatin
      periocular on a monthly basis for a total duration of therapy of 6 months. Patients will be
      followed for 24 months .
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>all cause mortality</measure>
    <time_frame>two years</time_frame>
    <safety_issue>No</safety_issue>
    <description>measure the mortality rate for the two groups(Cancer-related death and non-Cancer-related death) at two years</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>side effects of carboplatin periocular injection in the Treatment of Retinoblastoma</measure>
    <time_frame>two years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measure the side effects(systemic check-up, local side effects) before each treatment, and 1,3,6,9,12,18,24 months after the treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Retinoblastoma</condition>
  <arm_group>
    <arm_group_label>carboplatin periocular injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20mg/2ml carboplatin periocular injection together with  CEV chemotherapy(CEV Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin periocular injection</intervention_name>
    <description>20mg/2ml carboplatin periocular injection together with chemotherapy</description>
    <arm_group_label>carboplatin periocular injection</arm_group_label>
    <other_name>carboplatin</other_name>
    <other_name>vincristine, carboplatin, etoposide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
    <description>Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months.</description>
    <arm_group_label>chemotherapy</arm_group_label>
    <other_name>vincristine, carboplatin, etoposide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to provide written informed consent and comply with study assessments for the
             full duration of the study.

          -  linical diagnosis of retinoblastoma, Stage 0 or â…¡  base on International
             Retinoblastoma Staging System.

        Exclusion Criteria:

          -  Any previous disease in the study eye.

          -  Previous participation in any studies of investigational drugs within 1 month
             preceding Day 0 (excluding vitamins and minerals).

          -  History of chemical intervention for retinoblastoma in the study eye.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huasheng Yang, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Zhongshan Ophthalmic Center, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Huasheng Yang, M.D, PHD</last_name>
    <phone>+8620-87331539</phone>
    <email>yanghs64@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongshan Ophthalmic Center, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huasheng Yang, M.D, PHD</last_name>
      <phone>+8620-87331539</phone>
      <email>yanghs64@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 13, 2014</lastchanged_date>
  <firstreceived_date>May 10, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Huasheng Yang</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>Retinoblastoma</keyword>
  <keyword>carboplatin</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Retinoblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
